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Riluzole reduces amyloid beta pathology,
improves memory, and restores gene
expression changes in a transgenic mouse
model of early-onset Alzheimer’s disease
Masahir Okamoto1,2, Jason D. Gray1, Chloe S. Larson1,3,4, Syed Faraz Kazim3,4, Hideaki Soya2, Bruce S. McEwen1 and
Ana C. Pereira3,4
Abstract
Alzheimer’s disease (AD) represents a major healthcare burden with no effective treatment. The glutamate modulator,
riluzole, was shown to reverse many AD-related gene expression changes and improve cognition in aged rats.
However, riluzole’s effect on amyloid beta (Aβ) pathology, a major histopathological hallmark of AD, remains unclear.
5XFAD transgenic mice, which harbor amyloid β precursor protein (APP) and presenilin mutations and exhibit early Aβ
accumulation, were treated with riluzole from 1 to 6 months of age. Riluzole signiﬁcantly enhanced cognition and
reduced Aβ42, Aβ40, Aβ oligomers levels, and Aβ plaque load in 5XFAD mice. RNA-Sequencing showed that riluzole
reversed many gene expression changes observed in the hippocampus of 5XFAD mice, predominantly in expression
of canonical gene markers for microglia, speciﬁcally disease-associated microglia (DAM), as well as neurons and
astrocytes. Central to the cognitive improvements observed, riluzole reversed alterations in NMDA receptor subunits
gene expression, which are essential for learning and memory. These data demonstrate that riluzole exerts a disease
modifying effect in an Aβ mouse model of early-onset familial AD.
Introduction
Alzheimer’s disease (AD) is the most common neuro-
degenerative disorder, characterized by progressive
memory loss and cognitive decline1. Histopathologically,
AD exhibits an accumulation of amyloid plaques, formed
of amyloid β (Aβ) peptide, and of neuroﬁbrillary tangles
made of abnormally hyperphosphorylated tau protein2.
Presently, an estimated 5.5 million Americans suffer from
AD, and the prevalence is expected to signiﬁcantly
increase in the coming decades as the population ages3.
Currently, only symptomatic medications are available for
AD and there are no pharmacological therapies that alter
the progression of the disease. One of the greatest chal-
lenges for biomedical science today is to develop a
disease-modifying therapy for AD and related neurode-
generative disorders.
Riluzole can prevent age-related cognitive decline in
rats4 and in a transgenic mouse model of AD expressing
mutant human tau5. Riluzole is FDA approved for the
treatment of amyotrophic lateral sclerosis (ALS)6, and is
known to modulate the glutamatergic system5,7,8. Clus-
tering of dendritic spines in the hippocampus, which form
the post-synaptic component of most excitatory synap-
ses9, is one potential neuroplastic mechanism underlying
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riluzole’s efﬁcacy4, because clustering of synaptic inputs
has been shown to strengthen neural communication10,11.
Additionally, riluzole was reported to rescue age-related
gene expression changes in the rat hippocampus, along
with many gene pathways implicated in AD7. The hip-
pocampus is a region in the medial temporal lobe critical
for learning and memory and one of the regions com-
promised ﬁrst in the progression of AD, causing sig-
niﬁcant memory loss in affected individuals12,13.
However, the effect of riluzole on amyloid pathology, a
hallmark of AD and considered to be one of the important
triggers of the disease, is not well known. 5XFAD is a
mouse model of early-onset AD that harbors ﬁve Aβ
precursor protein (APP) and presenilin (PSEN) mutations
linked to familial forms of AD (i.e., APP KM670/671NL
(Swedish), APP I716V (Florida), APP V717I (London),
PSEN1 M146L, and PSEN1 L286V) leading to a robust
production of toxic Aβ peptides, amyloid plaque deposi-
tion, synaptic and neuronal loss, and memory deﬁcits14–
16. 5XFAD mice begin accumulating amyloid depositions
as early as two months of age, with evidence of neuronal
degeneration and synaptic loss starting at 4 months of age,
which is coincident with signiﬁcant memory impairment
in 4–5-month-old 5XFAD mice14. The present study
investigates riluzole’s effect on memory performance, Aβ
pathology, and hippocampal gene expression proﬁles in
5XFAD transgenic mice. The results of this study provide
further insight into the use of glutamate modulators as
potential disease-modifying therapies for AD.
Materials and methods
Animals
Young male 5XFAD (tg6799) mice (Jackson Labora-
tories) and strain-matched C57BL/6 (wild type) mice
(Jackson Laboratories) were housed in the animal vivar-
ium at The Rockefeller University for the duration of the
experiments. Mice were group-housed (3–5 animals/cage)
in climate-controlled conditions (30–50% humidity, 21 ±
2 °C, 12:12 h light/dark cycle) with ad libitum access to
food and water. Only male mice were used in this study to
control for any possible sex differences in gene expression
and behavior across the estrus cycle in female mice. All
procedures were performed in accordance with approved
protocols from The Rockefeller University’s Institutional
Animal Care and Use Committee (IACUC), according to
the PHS Policy on Humane Care and Use of Laboratory
animals.
Riluzole treatment
For these studies, one group of 5XFAD mice (n= 8) was
given ad libitum access to riluzole solution, i.e., 13 mg/kg
per mouse per day, a dose that has previously been
reported to improve cognition and reduce tau pathology
in P301L tau AD mice5,17, from 1 to 6 months of age (total
treatment duration= 5 months). A control group of
5XFAD mice (n= 7) and the wild-type (WT) mice (n=
10) had ad libitum access to tap water. For immunohis-
tochemical studies, a separate batch of 5XFAD mice was
treated with riluzole (n= 5) or tap water as control (n=
5). We chose sample sizes based on past literature uti-
lizing these methodologies4,7,18–20 with the intention to
minimize the number of animals to be used for the pre-
sent study.
Riluzole (R116; Sigma-Aldrich, St Louis, MO, USA) was
dissolved in room temperature tap water at a stock con-
centration of 0.12 mg/ml and stirred for ~6 h, covered by
foil to prevent light exposure. The stock solution was
diluted into the mouse drinking water based on (1)
average animal weight and, (2) water consumption over
the previous 24 h period and throughout the study, which
was measured by weighing the water bottles. We prepared
fresh riluzole solution after every 2nd to 3rd day during the
entire treatment period.
Behavioral testing
The Y-maze was used to test hippocampal-dependent
spatial memory retention as described previously4. One
day before Y-maze testing, mice were habituated to an
open ﬁeld (OF) in the same room where the test would
take place. Mice were acclimated to the room for 1 h
before being placed in the OF (45 × 45 cm, ~20 lux on
edges, ~40 lux in center) for 15 minutes. The OF was
sprayed with 70% ethanol between trials. After 24 h, mice
were tested in the Y-maze. During the 10-min acquisition
phase, mice were placed in the “start” arm and allowed to
explore the “start” and “familiar” arm while a “novel” arm
was blocked. After a 1-hr delay, the mice were placed back
in the “start” arm for a 10-min trial and allowed to explore
all three arms. The dimensions of each arm were 9 cm ×
40 cm. Corncob bedding from the cage of the mice being
tested was mixed with clean bedding and placed evenly on
the ﬂoor of the maze to reduce anxiety. The light in the
maze was ~25 lux in the arms and ~40 lux in the center.
To ensure that the preference for the novel arm was not
based on external factors, the start, familiar, and novel
arms were changed for each mouse. Cues of different sizes
and patterns were placed on the curtain surrounding the
maze facing each of the three arms to aid the mice in
spatial orientation. Time in each arm, as well as frequency
of entries, distance, and velocity were automatically
recorded and tracked by Noldus Ethovision video tracking
system and therefore were not blinded. Ratios of start /
(start+ familiar) for acquisition and novel / (novel+
familiar) for trial were calculated using the time spent in
those arms. The rationale for the test is that a mouse with
intact memory should spend a higher percentage of time
in the novel arm during the trial phase due to their ten-
dency to explore novel environments.
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Tissue harvesting, immunoblotting, and ELISA
For biochemical studies, the mice were sacriﬁced by
cervical dislocation, and brain tissue was immediately
dissected into hippocampal and cortical regions, and ﬂash
frozen cortical brain tissue was homogenized in tissue
homogenization buffer21,22 using a Teﬂon glass homo-
genizer. The BCA assay (23227, Thermo Fisher, IL, USA)
was used to determine the protein concentrations of the
homogenates. Six mice were selected at random from
each group for the biochemical studies.
Western blotting was used to quantify the full-length
APP (murine plus human) expression. 20 μg protein from
each sample was resolved under reducing conditions on a
15-well, 4–12% Bis-Tris gel (Invitrogen, Carlsbad, CA) at
100 V for 90min, then transferred to a PVDF membrane
at 30 V for 90min. The membrane was blocked in 1%
non-fat powdered milk. An anti-APP/Aβ antibody
(800704, Biolegend; reactive to amino acids 17–24 of
APP/Aβ, recognizes both murine and human APP/Aβ;
4G8) was used at a 1:1,000 dilution; secondary antibody
was anti-mouse at a 1:5,000 dilution. An anti-β-actin
antibody (4970, Cell Signaling Technology, MA, USA)
was used as a loading control at a 1:5,000 dilution; sec-
ondary antibody was anti-rabbit (R1006, Kindle Bios-
ciences) at a 1:20,000 dilution. The membrane was imaged
using KwikQuant digital imager (Kindle Biosciences).
Enzyme-linked immunosorbent assays (ELISAs) were
used to quantify the amount of Aβ42 and Aβ40 peptide
fragments and Aβ oligomers. Diethylamine (DEA)-soluble
Aβ was extracted from the cortical brain tissue homo-
genate according to Casali and Landreth protocol21,22.
The DEA-soluble portion was used in two ELISA kits
(Aβ42: KMB3441, Invitrogen; Aβ40: KMB3481, Invitro-
gen) as per manufacturer’s instructions. Samples were
diluted 1:2 for the Aβ40 ELISA and 1:10 for the Aβ42
ELISA. For Aβ oligomers, cortical brain tissue homo-
genate was diluted 1:10 and used in an ELISA kit (27725,
IBL America) according to the manufacturer’s instruc-
tions. All ELISAs were read on a microplate reader
(SpectraMax190; Molecular Devices) at 450 nm.
Tissue processing and immunohistochemistry
For immunohistochemical studies, the mice were
anesthetized with 125 mg/kg body weight of sodium
pentobarbital intraperitoneally and transcardially perfused
with 0.01M phosphate buffered saline (PBS), followed by
4% paraformaldehyde (PFA) in 0.01M PBS. After perfu-
sion, the brains were removed from the skull immediately,
and immersed in 4% PFA in 0.01M PBS for 24–48 h, and
then transferred to a 30% (w/v) sucrose solution at 4 °C
for 24–48 h. The ﬁxed brain tissues were stored at −80 °C
till further analysis. Later, sagittal sections were cut at a
thickness of 40 microns on a cryostat. The sections were
stored in glycol anti-freeze solution (30% ethylene glycol
and 30% glycerol in 0.01M PBS) at −20 °C.
For TS+ plaque load quantiﬁcation, every 10th section
was chosen based on systematic random sampling
(roughly 4–5 sections/animal) from 5 mice/group. A
modiﬁed thioﬂavin-S staining protocol23 was used on
free-ﬂoating brain sections, as reported previously20,24.
Brieﬂy, the sections were washed in copious volumes of
distilled water and were then incubated in 0.25% KMnO4
for 4–5min. After a brief wash with water, the sections
were then treated with a solution of 1% K2S2O5 and 1%
oxalic acid for 40–60 s until the brown color completely
disappeared. Sections were then incubated in 0.05%
thioﬂavin-S solution in dark for 8 min followed by two
1min washes in 80% ethanol. Subsequently, the sections
were washed thrice in distilled water for 1 min each.
Sections were mounted and cover-slipped with Fluorogel
mounting medium (Electron Microscopy Sciences, PA,
USA). Maximum intensity projection images of confocal
z-stacks were obtained with Leica SP5 DMI confocal
microscope. Images were thresholded and TS+ plaque
area in the subiculum region of the hippocampal forma-
tion and the frontal cortex was calculated using NIH
Image J (v.1.46r).
RNA-sequencing
Whole hippocampal mRNA was extracted from ﬂash
frozen tissue using the RNeasy Lipid Tissue Mini Kit
(Qiagen; #74804). RNA concentration and quality were
determined using a Bioanalyzer (Agilent). Samples with a
RIN > 8 (RNA Integrity Number) were used for sequen-
cing. Individual mice were separately pooled to generate
three replicate sequencing libraries for each condition.
The three libraries/group were prepared from the fol-
lowing mice: WT, n= 10 (pooled 3, 3, 4 mice); 5XFAD, n
= 7 (pooled 2, 2, 3 mice); and 5XFAD-Riluzole, n= 8
(pooled 2, 3, 3 mice). Sequencing libraries were prepared
using the TrueSeq Stranded mRNA Kit (Illumina) by the
RU Genomics Core facility. Libraries were barcoded to
allow for multiplexing in a single ﬂow cell. 75 bp single
strand reads were collected on a NexSeq 500 (Illumina) at
a sequencing depth of ~45 million reads per sample.
Using Galaxy25,26 Fastq ﬁles were checked for quality by
FastQC. Sequencing artifacts and residual adapter
sequences were removed by trimming reads by 10 bp at
the 5′ ends and then ﬁltering to exclude reads with quality
scores < 20. TopHat227 was used to align read to the
mouse genome (mm10). Bam ﬁles were loaded into
Strand NGS (Agilent) for quantiﬁcation of read density
using DESeq. Signiﬁcant genes in the differential expres-
sion analyses were identiﬁed using z-tests that were
Benjamin–Hochberg corrected for false discovery rates at
p < 0.05 and applying a cutoff of 1.5 × fold change. Venn
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diagrams, heatmaps, and scatter plots were generated
using Strand NGS visualization tools.
Signiﬁcant gene lists were uploaded to the DAVID
bioinformatics website (http://david.abcc.ncifcrf.gov).
Using the functional annotation clustering tool, enrich-
ment scores, and GO terms were obtained. Enrichment
scores above 1.3 were considered signiﬁcant28. The
enrichment scores from clusters with similar GO terms
were used to compare pathways that were altered in both
riluzole and 5XFAD conditions. Histograms were gener-
ated in Excel (Microsoft).
qRT-PCR
Human APP transgene expression was determined
using qRT-PCR. The cDNA was synthesized from 1500 ng
of hippocampal mRNA using High Capacity cDNA
Reverse Transcription Kit (Thermo Fisher Scientiﬁc).
qRT-PCR was performed with QuantStudio 12 K Flex
Real-Time PCR System (Thermo Fisher Scientiﬁc) using
TaqMan probes (APP, Hs 00169098_m1) to detect the
human APP transgene. Samples were run in triplicate
with a 20 µl reaction volume and compared using the
ΔΔCT method of relative quantiﬁcation29. GAPDH (Mm
99999915_g1) was used as a normalization control.
Data analysis
The details of RNA-Seq data analysis have been
described in its relevant section. For behavioral and bio-
chemical experiments, data were analyzed using one-way
analysis of variance (ANOVA) followed by Tukey’s post
hoc test. Pearson correlation analysis was used to study
correlations between behavior and ELISA data. For
immunohistochemistry data, the difference in Aβ plaque
load between study groups was determined by employing
Student’s t-test. The normality of the data was determined
using the Shapiro–Wilk and Kolmogorov–Smirnov tests.
There was no obvious difference in the variance between
groups for each test. Statistical analysis was performed
using GraphPad Prism 7.03 (GraphPad Software Inc.,
LaJolla, CA, USA). For all comparisons, p < 0.05 was
considered as statistical signiﬁcance level.
Results
Riluzole improves hippocampus-dependent memory in
5XFAD mice
5XFAD mice were treated with riluzole (13mg/kg p.o.)
from 1 month of age, prior to any evidence of amyloid
accumulation in the 5XFAD mice, until 6 months of age,
when the behavioral effects of amyloid accumulation are
readily apparent14. Treated (5XFAD-Riluzole) and
untreated (5XFAD) 5XFAD mice were compared against
wild-type (WT) mice in the Y-maze, a hippocampus-
dependent cognitive test30,31 at 4 and 6 months of age. No
signiﬁcant difference in Y-maze performance was
observed at 4 months of age (data not shown), suggesting
that 5XFAD mice had not yet manifested impaired
memory. At 6 months of age, the acquisition trial did not
Fig. 1 Riluzole treatment rescues cognitive impairment in 5XFAD
mice. a In Y-Maze, there were no signiﬁcant differences among
groups in the ratio of time spent in familiar and start arms during the
acquisition phase (F(2,22)= 2.269, p= 0.1271). b There were
signiﬁcant differences among groups in the ratio of time spent in the
novel and familiar arms during the trial phase (F(2,21)= 8.736, p=
0.0017): between wild type (WT) and 5XFAD (p= 0.0012) and between
5XFAD and 5XFAD-Riluzole mice (p= 0.04), with WT and 5XFAD-
Riluzole mice spending a signiﬁcantly higher percentage of time in
the novel arm. c There were no signiﬁcant differences in distance
traveled during the trial phase (F(2,21)= 1.673, p= 0.2117). The Y-
maze data is presented as mean ± S.E.M., and based on WT, n= 10;
5XFAD, n= 6; and 5XFAD-Riluzole, n= 8 mice. *p < 0.05; **p < 0.01
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show any difference amongst the three groups (Fig. 1a; F
(2,22)= 2.269, p= 0.1271, one-way ANOVA). However,
one animal in the 5XFAD group failed to show equal time
in each arm during acquisition and therefore it was
excluded from the ﬁnal behavioral analysis (WT, n= 10;
5XFAD, n= 6; 5XFAD-Riluzole, n= 8). In the retention
trial the percentage of time spent exploring the novel arm
(exploration time in novel arm/exploration time in novel
+ familiar arm) showed a signiﬁcant difference between
the three groups (Fig. 1b; F(2,21)= 8.736, p= 0.0017,
one-way ANOVA). 5XFAD mice showed signiﬁcant
memory impairment as compared to WT controls (Fig.
1b; p= 0.0012, Tukey’s post hoc test); riluzole treatment
signiﬁcantly ameliorated this deﬁcit in 5XFAD mice (Fig.
1b; 5XFAD vs. 5XFAD-Riluolze, p= 0.04, Tukey’s post
hoc test). Also, 5XFAD-Riluzole mice displayed
similar performance in retention trial as WT controls,
suggesting that the treatment with riluzole restored spa-
tial reference memory of 5XFAD mice to WT control
levels (Fig. 1b; p= 0.2615, Tukey’s post hoc test). The
total distance traveled did not differ signiﬁcantly among
groups (Fig. 1c; F(2,21)= 1.673, p= 0.2117, one-way
ANOVA), indicating that locomotor activity did not
affect the results.
Riluzole treatment reduces Aβ pathology that inversely
correlates with memory performance in 5XFAD mice
We utilized multiple methodologies to assess Aβ
pathology including immunoblotting for full-length APP
estimation, ELISAs for major Aβ toxic isoforms, Aβ 42
and Aβ 40, and Aβ oligomers, qRT-PCR based quantiﬁ-
cation of human APP mRNA transcripts, and immuno-
histochemical quantiﬁcation of amyloid plaque load by
thioﬂavin-S staining, to identify riluzole’s effect on dif-
ferent Aβ isoforms and aggregates that have been shown
to have diverse roles in AD pathophysiology32,33. First,
immunoblotting revealed a several-fold higher full-length
APP protein expression in 5XFAD mice as compared to
WT controls (Fig. 2a, b; p= 0.0009, Tukey’s post hoc
test). Riluzole treatment signiﬁcantly reduced APP pro-
tein expression in 5XFAD mice (Fig. 2a, b; p= 0.028,
Tukey’s post hoc test). The APP protein expression did
not differ signiﬁcantly between WT and 5XFAD-Riluzole
groups (p= 0.22; Tukey’s post hoc test). Second, an
ELISA-based assay for the most toxic and amyloidogenic
Aβ isoform, Aβ42, showed a signiﬁcant difference
between groups (Fig. 2c; F(2,15)= 18.60, p < 0.0001), with
Tukey’s post hoc analysis showing a difference between
WT and 5XFAD (p < 0.0001) and between 5XFAD and
5XFAD-Riluzole mice (p= 0.0108). Even though riluzole
treatment signiﬁcantly reduced Aβ42 levels, the levels
were still signiﬁcantly higher in 5XFAD-Riluzole mice as
compared to WT controls (p= 0.0406). Third, Aβ40
ELISA showed a signiﬁcant difference between groups
(Fig. 2d; F(2,15)= 12.9, p= 0.0005), with Tukey’s post hoc
analysis showing a statistically signiﬁcant difference
between WT and 5XFAD (p= 0.0004) and between
5XFAD and 5XFAD-Riluzole mice (p= 0.0141). No sig-
niﬁcant difference was found between 5XFAD-Riluzole
and WT groups (p= 0.2166). Fourth, an ELISA-based
assay for Aβ oligomers showed a signiﬁcant difference
between groups (Fig. 2e; F(2,15)= 12.00, p= 0.0008), with
post hoc analysis showing a signiﬁcant difference between
WT and 5XFAD (p= 0.0009) and between 5XFAD and
5XFAD-Riluzole mice (p= 0.0057). There was no statis-
tically signiﬁcant difference between 5XFAD-Riluzole and
WT groups (p= 0.6316). These results demonstrate that
riluzole reduced the levels of toxic Aβ species, i.e., Aβ42,
Aβ40, and Aβ oligomers.
Consistent with previous ﬁndings in 5XFAD and other
APP/PSEN mutations AD mice34,35, levels of toxic Aβ
species showed signiﬁcant negative Pearson correlations
with Y-maze performance with each of the isoforms tes-
ted, including Aβ42 (Fig. 2f; r2= 0.6716, p < 0.0001), Aβ40
(Fig. 2g; r2= 0.5722, p= 0.0004), Aβ oligomers (Fig. 2h;
r2= 0.5076, p= 0.0013). Notably, the strongest inverse
correlation was with Aβ42, considered to be the most
toxic Aβ species.
To determine if riluzole treatment altered APP trans-
gene expression in 5XFAD mice, qRT-PCR using human
APP speciﬁc primers was performed on hippocampal
mRNA. The qRT-PCR analysis revealed, as expected, no
expression of human APP in WT mice (Fig. 2i). The
comparison of 5XFAD-Riluzole and 5XFAD controls
revealed a trend towards reduction in riluzole-treated
5xFAD mice, however it did not reach statistical sig-
niﬁcance (Fig. 2i; p= 0.08, Student’s t-test).
We further evaluated the effect of riluzole treatment on
Aβ pathology in 5XFAD mice by performing TS+-Aβ
plaque load quantiﬁcation (Fig. 2j–m). Quantiﬁcation of
TS+ stained Aβ plaques showed a signiﬁcant reduction in
riluzole-treated 5XFAD mice in the subiculum region of
the hippocampus (Fig. 2j, k; 5XFAD vs. 5XFAD-Riluzole,
Student’s t-test, p < 0.001). Also, riluzole treatment sig-
niﬁcantly reduced TS+-plaque area in the frontal cortex
region of 5XFAD mice (Fig. 2l, m; 5XFAD vs. 5XFAD-
Riluzole, Student’s t-test, p < 0.001).
Riluzole treatment rescues differentially expressed genes
in the hippocampus of 5XFAD mice
Differential expression analysis of RNA-Sequencing
(RNA-Seq) data from hippocampal mRNA from each
condition revealed that untreated 5XFAD mice had sig-
niﬁcantly altered expression of 1541 genes (1318 upre-
gulated and 223 downregulated) compared to WT mice
(Fig. 3a). Riluzole treatment of 5XFAD mice altered
expression of 830 (416 upregulated, 414 downregulated)
genes compared to untreated 5XFAD mice (Fig. 3a).
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Fig. 2 (See legend on next page.)
Okamoto et al. Translational Psychiatry  (2018) 8:153 Page 6 of 13
Importantly, 247 genes were found to be changed by both
the 5XFAD transgene and riluzole treatment of the
transgenic mice, suggesting they might be central not only
to the pathology of AD, but also riluzole’s ability to
reverse its effects. To further characterize this effect, a
scatter plot of the fold change of the overlapping genes in
each condition was generated (Fig. 3b). This showed
riluzole treatment reversed the direction of change in
expression for 86.6% of these genes, with 188 genes that
increased with 5XFAD and were decreased with riluzole
treatment (lower-right quadrant) and 26 genes that were
decreased with 5XFAD and were increased with riluzole
treatment (upper left quadrant). To investigate the effect
of riluzole treatment on the endogenous APP, the
expression of mouse APP mRNA was calculated from
RNA-Seq data showing no signiﬁcant difference in
endogenous APP mRNA levels (Fig. 3c; F(2,6)= 0.6825,
p= 0.09).
The overlapping 247 differentially expressed genes from
the 5XFAD vs. WT and 5XFAD vs. 5XFAD-Riluzole
comparisons were assigned to functional pathways using
the DAVID bioinformatics database. Enrichment scores
from common GO pathways were summed to identify
groups of genes implicated in riluzole’s ability to rescue
AD (Fig. 3d). Histograms of the summed enrichment
scores illustrate pathways that were upregulated with
5XFAD and downregulated with riluzole, or down-
regulated with 5XFAD and upregulated with riluzole.
Functional analysis via DAVID and assignment to GO
categories revealed that riluzole reversed the pathways
related to Immunity and Glycoproteins (Fig. 3e, f). For
example, BMP4 and BMP6 are elevated in AD and
implicated in neurogenesis36,37 and reversed by riluzole.
Many of the immune genes were related to the innate
immune system, such as IFIT3, CLEC7A, TRIM14, OAS2,
and OAS3 (Table 1). The innate immune system has been
implicated as a key mechanism of neuronal damage in
AD38.
Increasingly, researchers have characterized the dis-
tinct effects of AD on speciﬁc cell types of the brain.
Genes that are canonically neuronal, astrocytic, or
present primarily in microglia were selected based on a
previous publication39 and heatmaps illustrating their
change in expression across conditions were generated
(Fig. 4a–c). Consistent with previous RNA-Seq studies
in this mouse line40,41, microglia genes were nearly
universally upregulated in 5XFAD mice, and many of
them were downregulated by riluzole. For example, the
microglia-related genes Clec7a and IRF7 (Table 1)
expression are signiﬁcantly downregulated in 5XFAD
mouse hippocampus and rescued by riluzole. It has
been previously reported that Aβ42 peptide induces
IRF7 level and microglial inﬂammatory responses42.
Thus, riluzole appears to exert an inﬂuence on several
immune-related pathways implicated in AD. A recent
publication characterizing expression changes in the
5XFAD mice identiﬁed a unique population of disease-
associated microglia (DAM) as important for AD pro-
gression40. The present data conﬁrm an upregulation of
this speciﬁc microglia subclass of genes (DAM) in
5XFAD mice and that riluzole can reverse their upre-
gulation (Fig. 4d, e).
A similar pattern was observed for many, but not all of
the genes that are expressed predominately in neurons
and astrocytes (Fig. 4b, c). CLU, a gene previously asso-
ciated with AD by several GWAS studies, was rescued by
riluzole43,44. Riluzole also reversed expression changes in
genes related to neuroplasticity such, as ANK2, which is
implicated in spectrin actin cytoskeleton45 and Neﬂ,
important for neuroﬁlaments46. Rescue also occurs in
genes related to endocystosis, such as Necap147, and those
involved in the retromer transporter from endosome to
Fig. 2 Riluzole treatment reduces Aβ pathology which inversely correlates with memory performance in 5XFAD mice. a Representative
western blots of full-length APP protein expression are shown. The endogenous APP protein bands in WT mice appear faint because APP transgenic
mice have signiﬁcant overexpression, which required a short exposure time to obtain bands suitable for quantiﬁcation of 5XFAD lanes. b
Quantiﬁcation data showing that APP protein expression was signiﬁcantly different among groups (F(2,15)= 11.04, p= 0.0011): between wild type
and 5XFAD (p= 0.0009) and between 5XFAD and 5XFAD-Riluzole mice (p= 0.0279). c Soluble Aβ42 was signiﬁcantly different among groups (F(2,15)
= 18.60, p < 0.0001): between wild type and 5XFAD (p < 0.001) and between 5XFAD and 5XFAD-Riluzole mice (p= 0.0108). d Soluble Aβ40 was
signiﬁcantly different among groups (F(2,15)= 12.90, p= 0.0005): between wild type and 5XFAD (p= 0.0004) and between 5XFAD and 5XFAD-
Riluzole mice (p= 0.0141). e Aβ oligomers were signiﬁcantly different among groups (F(2,15)= 12.00, p= 0.0008): between wild type and 5XFAD (p
= 0.0009) and between 5XFAD and 5XFAD-Riluzole mice (p= 0.0057). f Aβ42 peptide (r2= 0.6716, p < 0.0001), g Aβ40 peptide (r2= 0.5722, p=
0.0004), and h Aβ oligomers (r2= 0.5076, p= 0.0013) each showed a signiﬁcant correlation between Aβ levels and memory performance in Y-maze. i
The qRT-PCR analysis revealed no expression of human APP in WT mice, and no statistically signiﬁcant difference between 5XFAD and 5XFAD-
Riluzole (p= 0.08). j, k Riluzole treatment signiﬁcantly reduced TS+ Aβ plaque area in the subiculum region of the hippocampus in 5XFAD mice (p <
0.001). l, m The Aβ plaque load in the frontal cortex was also signiﬁcantly reduced by riluzole in 5XFAD mice (p < 0.001). The data in panels (b–e, l, k,
m) is shown as mean ± S.E.M. The western blot data in panels (a, b) and ELISA data in panels (c–e) is based on WT, n= 6, 5XFAD, n= 6, and 5XFAD-
Riluzole, n= 6. The correlation data in panels (f–h) is based on WT, n= 6, 5XFAD, n= 5, and 5XFAD, n= 6. The qRT-PCR data in panel (l) is based on
WT, n= 10, 5XFAD, n= 7, 5XFAD-Riluzole, n= 8. The TS+ Aβ plaque load data in panels (j–m) is based on 5XFAD, n= 5, and 5XFAD-Riluzole, n= 5.
*p < 0.05, **p < 0.01, ***p < 0.001. Scale bar= 100 µm
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Golgi, Rab6b48. Both endocytosis and the retromer have
been implicated in AD pathophysiology49,50.
Proper expression and activation of hippocampal
synaptic NMDA receptors is critical for long-term
potentiation (LTP), learning, and memory51,52. In com-
parison to wild-type mice, 5XFAD mice were found to
have signiﬁcantly decreased expression levels of NMDA
subunits Grin1 (Fig. 4f, p= 0.0417) and Grin2a (Fig. 4f, p
= 0.0453), a trend towards reduced Grin2b expression
(Fig. 4f, p= 0.065), and increased level of Grin2d (Fig. 4f,
p= 0.0251). No statistically signiﬁcant difference was
observed in Grin2c expression between WT and 5XFAD
mice (Fig. 4f, p= 0.18). There appeared to be a trend
towards increase in Grin1, Grin2a, and Grin2b expression
and a decrease in Grin2c and Grin2d expression in
5XFAD-Riluzole vs. 5XFAD mice (Fig. 4f). More impor-
tantly, the expression level of Grin1, Grin2a, Grin2b,
Grin2c, and Grin2d did not differ signiﬁcantly between
5XFAD-Riluzole vs. WT mice (Fig. 4f; p= 0.6764, p=
0.3420, p= 0.2969, p= 0.9620, and p= 0.2059, respec-
tively). These data suggest that riluzole treatment
normalized these NMDA subunits expression levels to
WT controls.
Discussion
This study showed that riluzole exerted a disease-
modifying effect in an early-onset and aggressive mouse
model of AD. It prevented hippocampus-dependent
spatial memory decline in 5XFAD mice. A hallmark of
the 5XFAD mouse model is elevated levels of Aβ.
Riluzole treatment for 5 months signiﬁcantly reduced
full-length APP, Aβ42, Aβ40, Aβ oligomers levels, and
Aβ plaque burden in the brains of 5XFAD mice. Levels
of Aβ peptides strongly correlated with behavioral per-
formance. Furthermore, riluzole reversed many of the
gene expression changes resulting from the 5XFAD
transgenes. The most signiﬁcant effects were on
immune pathways, and speciﬁcally microglia-related
genes thought to be critical mediators of AD patho-
physiology53,54. Riluzole treatment also reversed many
of the changes in neuronal and astrocytic speciﬁc gene
expression proﬁles.
Fig. 3 Treatment of 5XFAD mice with riluzole rescues gene expression changes in the hippocampus. a Venn diagram illustrating the overlap
of 247 genes that were changed in 5XFAD compared to wild type and in 5XFAD mice treated with riluzole compare to untreated mice. b Scatter plot
illustrating the 247 overlapping genes showing fold change by 5XFAD (x-axis) against fold change with riluzole treatment on 5XFAD mice (y-axis).
86% of overlapping 5XFAD genes is reversed by riluzole treatment. The upper left quadrant represents 26 genes that had decreased expression with
5XFAD and increased expression after riluzole treatment. Conversely, the lower-right quadrant illustrates 189 genes that were increased with 5XFAD
and decreased by riluzole. c The mRNA expression of Mouse APP from RNA-Seq data revealed no signiﬁcant difference among WT, 5XFAD, and
5XFAD-Riluzole groups. d Histograms illustrating signiﬁcantly enriched pathways based on genes differentially expressed by overlapping gene.
(enrichment score > 1.3). e, f Histograms illustrating signiﬁcantly enriched pathways with the highest sum enrichment scores across opposite
conditions (Increased in 5XFAD and Decreased with riluzole treatment or vice-versa) based on differentially expressed genes (enrichment score > 1.3).
Similar pathways and enrichment scores were observed when comparing genes decreased by 5XFAD and increased by riluzole, as well as for genes
increased with age and decreased by riluzole. The RNA-Seq data is based on hippocampal tissue pooled into three replicate sequencing libraries/
group from WT, n= 10 (pooled 3, 3, 4 mice); 5XFAD, n= 7 (pooled 2, 2, 3 mice); and 5XFAD-Riluzole, n= 8 (pooled 2, 3, 3 mice)
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In AD, toxic Aβ (mainly Aβ42 and Aβ40) deposition
proceeds from oligomers to diffuse plaques, ultimately
leading to the formation of compact plaques, which can
be identiﬁed with thioﬂavin-S staining20,23,24. Even though
the precise etiological mechanism responsible for neuro-
degeneration and cognitive impairment in AD remains
elusive, evidence supports the hypothesis that Aβ triggers
pathological cascades, which ultimately culminate in
profound memory dysfunction55–58. Recent evidence
further implicates Aβ-induced neural network dysfunc-
tion and hyperexcitability as a major contributor to cog-
nitive impairment in AD59,60. In the present study, we
found that riluzole signiﬁcantly reduced Aβ pathology
including toxic Aβ isoforms, oligomers, and the plaque
load in 5XFAD mice. Remarkably, a strong inverse cor-
relation was found between Aβ pathology and cognitive
performance in these mice. This is in agreement with a
previous study in 5XFAD mice, which concluded that it is
ultimately cerebral amyloidosis that is responsible for
neurodegeneration and cognitive impairment in these
mice61. The present study suggests that the beneﬁcial
effect of riluzole on cognition in 5XFAD mice could be
because of reduction in Aβ pathology.
The mechanism of Aβ reduction by riluzole treatment
remains to be determined in future studies. In the present
study, we found that riluzole treatment showed a trend
towards reduction in human APP mRNA levels and a
signiﬁcant decrease in APP protein levels in 5XFAD mice.
This hints towards a probable transcriptional
downregulation and a likely translational downregulation
of APP by riluzole. This could have contributed to a
reduction in Aβ pathology in riluzole-treated 5XFAD
mice, however, an effect of riluzole on amyloidogenic
processing of APP or Aβ clearance cannot be ruled out.
There also remains a possibility that at least some of the
beneﬁcial effects of riluzole could be because of APP
reduction. APP was previously reported to be proin-
ﬂammatory and to regulate microglial phenotype in APP/
PS1 mice62,63. Also, APP overexpression was reported to
be a key mediator of network hypersynchronous activity
in AD mice64, recently hypothesized to be an important
contributory factor to cognitive impairment in AD60.
Thus, APP reduction by riluzole treatment in 5XFAD
could have contributed to microglial downregulation and
cognitive rescue. Nonetheless, as mentioned earlier, a
previous study showed prevention of neurodegeneration
and memory loss after genetic deletion of β-secretase
(BACE1; major enzyme involved in amyloidogenic pro-
cessing of APP) in 5XFAD mice61, suggesting the domi-
nant role of Aβ in memory performance in these mice.
The identiﬁcation of immune-related pathways is con-
sistent with previous RNA-Seq results from 5XFAD
mice40,41. Riluzole recovered several genes such as IFIT3,
CLEC7A, TRIM14, OAS2, and OAS3 of the innate
immune system, which have been thought to play a cru-
cial role as disease promoting factors in AD38. A recent
study performing single-cell transcriptional proﬁling in
5XFAD and wild-type mice revealed a microglia-like
Table 1 Pathways and gene list that were reversed with riluzole treatment
Pathways Genes that are upregulated with 5XFAD and downregulated
with riluzole
Pathways Genes that are downregulated with
5XFAD and upregulated with riluzole
Immunity BST2, CLEC7A, CYBB, H2-Q2, IFIT3, IRF7, LBP, LY9, MX1, MX2, Oas1a,
OAS2, OAS3, Oasl2, RSAD2, TNFRSF17, TRIM14
Glycoprotein Col6a4, HTR1B, IGFBPL1, IGSF9B, pcsk1, PI15,
SLC9A3
Glycoprotein 1500015O10Rik, ABCA4, ACE, AQP1, BMP4, BMP6, BST2, Ccl9, CD5,
CDH3, CLDN2, CLEC1A, CLEC7A, CLEC9A, COL17A1, COL4A3, COL4A4,
COL8A1, COL8A2, COL9A3, CXCL5, CYBB, Defb11, ENPP2, F5, FAP, folr1,
FOLR2, GLB1L2, H2-Q2, HCST, Iﬁ27l2a, IGFBP2, IGFBP5, IL15, ITPRIPL1,
KCNE2, KL, KRT18, KRT8, LARGE2, LBP, LGALS3BP, LY9, MAMDC2,
MFRP, Mfsd4b1, MIA, NOX1, oacyl, OAS2, OCA2, PRLR, SCTR, SEMA3B,
SFRP1, SLAMF8, SLC2A12, SLC39A4, Slco1a5, SOSTDC1, SULF1, tmc8,
TMPRSS11A, TNFRSF17, TNFSF8, TNS4, TTR, Vmn2r84, WFDC2,
WFIKKN2
Signal Col6a4, IGFBPL1, IGSF9B, pcsk1, PI15
Cell junction IGSF9B
Collagen COL17A1, COL4A3, COL4A4, COL8A1, COL8A2, COL9A3, MFRP, TNFSF8
Netrin domain SFRP1, WFIKKN2
GTP binding 9330111J21Rik1, GBP3, Gm12185, Gm4951, Gm5431, GNA15, MX1,
MX2, RAB20, RHOD
Scanvenger receptor
activity
CD5, ENPP2, LGALS3BP
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population associated with neurodegeneration40, and it
identiﬁed activation genes as key mediators of disease
pathology. Notably, riluzole reversed several of these
genes including those related to TREM2 independent
mechanisms, such as Cx3cr1, P2ry12, Tyrobp, Ctsb, B2m,
and Lyz2, as well as TREM2 dependent genes, such as
TREM2, Axl, Cst7, Ctsl, Ccl6, Itgax, Clec7a, and Lilrb4.
These ﬁndings also converge with a growing human AD
literature that suggest immune pathways, and most spe-
ciﬁcally the innate immune system and microglia-related
genes as being importantly involved in the pathophysiol-
ogy of AD38,53,54. Riluzole, therefore, rescues several
immune-related pathways that may be critical in AD
progression and cognitive dysfunction.
The effect of riluzole on cell-type-speciﬁc genes
expressed predominantly in microglia, neurons, and
astrocytes39 were investigated in 5XFAD mice. Heatmaps
to visualize the expression levels of genes canonically
associated with each of these cell types demonstrate that
riluzole profoundly reverses the effects of the 5XFAD
transgene on microglial gene expression, speciﬁcally the
novel population of DAM40 (Fig. 4d, e). Further, expres-
sion levels of the gene CLU, which has been shown in
multiple human genetic studies to be associated with an
increased risk for AD43,44, could also be rescued in the
5XFAD mice treated with riluzole. Riluzole also rescued
genes related to endocytosis (for example, Necap1)47 and
the retromer transporter from endosome to Golgi,
Fig. 4 Expression changes in cell-type-speciﬁc markers and hippocampal NMDA receptor subunits are reversed by riluzole treatment.
Heatmap showing 23–25 canonical expression markers for hippocampal (a)microglia39, b astrocytes39, c neurons39, and (d, e) a unique population of
disease-associated microglia (DAM)40. Riluzole showed a rescue effect in neuronal and astrocytic populations. The rescue was most pronounced in
microglia-related genes, and in particular DAM, which are associated with neurodegeneration. f 5XFAD mice have a signiﬁcantly decreased
expression levels of NMDA subunits Grin1 (p= 0.0417) and Grin2a (p= 0.0453), a trend towards reduced Grin2b (p= 0.065), and increased levels of
Grin2d (p= 0.0251) in comparison to wild-type animals. Riluzole modulated the NMDA subunits expression levels in 5XFAD mice to WT control levels
(5XFAD-Riluzole vs. WT; Grin1, p= 0.6764, Grin2a, p= 0.3420, Grin2b, p= 0.2969, Grin2c, p= 0.9620, Grin2d, p= 0.2059. The RNA-Seq data are based
hippocampal tissue pooled into three replicate sequencing libraries/group from WT, n= 10 (pooled 3, 3, 4 mice); 5XFAD, n= 7 (pooled 2, 2, 3 mice);
and 5XFAD-Riluzole, n= 8 (pooled 2, 3, 3 mice). *p < 0.05
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Rab6b48. Both endocytosis and the retromer dysfunction
have been reported to be involved in the pathophysiology
of AD in human genetic and neuropathologic studies49,50.
Consistent with previous ﬁndings in aged rats, the iden-
tiﬁcation of genes related to neural transmission and
plasticity that were rescued by riluzole treatment7 support
the hypothesis that clustering of dendritic spines is a
potential mechanism by which riluzole is able to improve
cognition4.
A growing scientiﬁc literature suggests glutamatergic
dysregulation is an essential aspect of the pathophysiology of
AD. First, excitatory pyramidal neurons are more vulnerable
to cell death in AD65,66. The hippocampal and neocortical
atrophy visible in AD brains demonstrates degeneration
predominantly in large glutamatergic pyramidal neurons66.
Second, β-amyloid and tau release and tau propagation are
dependent on excitatory neural activity67–70. Third, toxicity
of these AD-related proteins is likely dependent on gluta-
matergic dysfunction. For example, Aβ oligomers have been
shown to disrupt glutamate transporters71, inhibiting LTP,
critical for learning, and memory, and leading to activation of
extrasynaptic NMDA receptors72, which has been associated
with long-term depression and excitotoxicity73. We have
observed in this study that riluzole rescued hippocampal
expression of NMDA receptor subunits in 5XFAD to wild-
type levels which play an essential role in LTP, learning, and
memory formation74,75. These NMDA receptor subunits
included synaptic NMDA receptor Grin2a (NMDAR2A,
GluN2A) and the more abundant extrasynaptic NMDA
receptor Grin2b (NMDAR2B, GluN2B)76,77, suggesting
riluzole may affect the NMDA receptor subunits dynamics
in a complex manner in both synaptic and extrasynaptic
spatial domains. The timing and magnitude of activation of
these receptors should be investigated in future studies as
transient and intense activation of synaptic NMDA receptors
by trans-synaptic glutamate release has been thought to be
neuroprotective and important for learning and memory
while a chronic activation of extrasynaptic NMDA receptors
by sustained glutamate elevation in the extrasynaptic space
could contribute to excitotoxicity73.
Importantly, activation and maturation of microglia is
dependent on glutamate levels78,79, which could possibly
explain the robust effect on microglia-related gene
expression we observe with the glutamate modulator
riluzole treatment. In addition, Aβ is known to induce
microglia80–82 and the observed DAM reversal in treated
animals could be an effect of reduced Aβ levels induced by
riluzole or other potential mechanisms. In summary,
glutamatergic dysregulation appears to be implicated in a
cycle of toxicity in AD through several pathways,
including microglia-mediated neuroinﬂammation, exci-
totoxicity, release and toxicity of Aβ, and tau release and
tau propagation. We hypothesize that modulation of
glutamatergic neurons and synapses in AD, the most
susceptible to degeneration and the best predictor of
cognitive decline in AD83–85, can signiﬁcantly mitigate
toxicities through multiple pathways in AD.
Future studies will investigate the mechanisms through
which the glutamate modulator riluzole prevented cog-
nitive decline in this aggressive amyloid pathology mouse
model of AD. Together, these ﬁndings suggest that rilu-
zole’s regulation of the glutamatergic synapse plays a
critical role in reducing Aβ levels and restoring expression
of genes implicated in both microglial activation and
synaptic transmission.
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